William Adams, DO
Family Medicine · Rigby, IDNPI 1467403733
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$895
- AstraZeneca$334
- Astellas Pharma US Inc$310
- Amgen$279
- Johnson & Johnson$218
- Lilly USA, LLC$207
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,76299%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $895 |
| AstraZeneca(2 entities) | 22 | $334 |
| Astellas Pharma US Inc | 18 | $310 |
| Amgen(2 entities) | 16 | $279 |
| Johnson & Johnson | 15 | $218 |
| Lilly USA, LLC | 15 | $207 |
| GSK | 14 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $150 |
| Pfizer | 10 | $146 |
| Novo Nordisk | 8 | $121 |
| Boehringer Ingelheim | 7 | $108 |
| Teva Pharmaceuticals USA, Inc. | 6 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| Boston Scientific | 4 | $71 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Exact Sciences | 3 | $56 |
| Edwards Lifesciences | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Neurelis, Inc. | 2 | $34 |
| Novartis | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Biogen | 1 | $17 |
| Corium, LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $13 |
How this compares
$3,783 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $96,432 |
| EliquisApixaban | 120 | $91,101 |
| JardianceEmpagliflozin | 33 | $22,630 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $22,052 |
| OzempicSemaglutide | 15 | $17,365 |
| MounjaroTirzepatide | 12 | $14,527 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,941 |
| Nurtec OdtRimegepant Sulfate | 13 | $12,439 |
| LinzessLinaclotide | 14 | $8,766 |
| FarxigaDapagliflozin Propanediol | 12 | $6,728 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,181 |
| SavellaMilnacipran Hcl | 11 | $5,397 |
| MyrbetriqMirabegron | 11 | $4,758 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 218 | $4,113 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $146 | $103,540133 claims |
| Boehringer IngelheimJardiance | $108 | $22,63033 claims |
| GSKTrelegy Ellipta | $201 | $22,05224 claims |
| Novo NordiskOzempic | $121 | $17,36515 claims |
| Lilly USA, LLCMounjaro | $207 | $14,52712 claims |
| AbbVieLinzess, Savella | $895 | $14,16325 claims |
| AstraZenecaFarxiga | $334 | $6,72812 claims |
| Astellas Pharma US IncMyrbetriq | $310 | $4,75811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.
Other family medicine in Rigby
- Richard HarperRigby$4K
- Kenneth CongerSandpoint$266K
- David ButukMeridian$206K
- Anne BroadwayIdaho Falls$184K
- Timothy McHughMeridian$165K
- Phyllis YouBoise$88K
- Ralph SutherlinSt Maries$73K
- Henry DownsCoeur D Alene$69K
- Crystal PyrakCoeur D Alene$46K
- Gary SoucieBlackfoot$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.